300+ Compound Library

ViroStatics has obtained an exclusive license to a library of 300 compounds developed by Professor Maurizio Botta (University of Siena) in collaboration with Professors Silvia Schenone (University of Genova) and Giovanni Maga (IGM-CNR, Pavia).  The library consists of specifically designed molecules targeting key enzymes and processes involved in both cancer and viral diseases.

ViroStatics will identify and develop candidate compounds with activity against HIV (the virus that causes AIDS), hepatitis C, and other viruses using the Company's proprietary screening methodologies.

The Company seeks partners for the development of these compounds in the oncology space. In vivo proof of concept has been shown for Burkitt's lymphoma and osteosarcoma as well as in imatinib (Gleevec) resistant [T315I] CML and ALL.